Predictive Clinical and Biological Parameters in Breast Cancer

Conditions

Breast Cancer

Keywords

breast cancer

Brief summary

Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation

Renaud Sabatier, S. Garnier, Nadine Carbuccia, Arnaud Guillé, Carole Tarpin et al. (7 authors)

Annals of Oncology2018-09-01

10.1093/annonc/mdy316.001

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.

Gonçalves A, Bertucci F, Guille A, Garnier S, Adelaide J, Carbuccia N, Cabaud O, Finetti P, Brunelle S, Piana G, Tomassin-Piana J, Paciencia M, Lambaudie E, Popovici C, Sabatier R, Tarpin C, Provansal M, Extra JM, Eisinger F, Sobol H, Viens P, Lopez M, Ginestier C, Charafe-Jauffret E, Chaffanet M, Birnbaum D.

2016-11-0115 citations

10.18632/oncotarget.12714

Abstract P4-13-23: Next-generation sequencing (NGS), array comparative genomic hybridization (aCGH) and patient-derived tumor xenograft (PDX) for precision medicine in advanced breast cancer: A single-center prospective study

Anthony Gonçalvès, François Bertucci, Max Chaffanet, Arnaud Guillé, S. Garnier et al. (26 authors)

Cancer Research2016-02-15

10.1158/1538-7445.sabcs15-p4-13-23

Interventions

GENETICmolecular alteration

research of molecular alteration

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* breast cancer * age \> 18 * signed informed consent

Exclusion criteria

* emergency

Design outcomes

Primary

Measure	Time frame	Description
molecular alteration in breast cancer	average of 4 weeks after diagnosis	gene expression level

Secondary

Measure	Time frame	Description
relation between molecular alteration and clinical and histological characteristics	up to 3 years	hazard ratio between molecular alteration and clinical and histological characteristics

Countries

France

Contacts

PRINCIPAL_INVESTIGATORCarole TARPIN, MD

Institut Paoli-Calmettes

Outcome results

None listed